[Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Kageyama
Shigeru
S
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects; D001713:Biphenyl Compounds; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects; D003371:Cough / Q000139:chemically induced; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007564:Japan; D019808:Losartan / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000008:administration & dosage / Q000009:adverse effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D002216:Captopril; D019808:Losartan; C081643:candesartan